The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
1,026 Experimental treatments in acute stroke
Abstract
Objective: Preclinical evaluation of neuroprotectants fostered high expectations of clinical efficacy. When not matched, the question arises whether experiments are poor indicators of clinical outcome or whether the best drugs were not taken forward to clinical trial. Therefore, we endeavored to contrast experimental efficacy and scope of testing of drugs used clinically and those tested only experimentally. Methods: We identified neuroprotectants and reports of experimental efficacy via a systematic search. Controlled in vivo and in vitro experiments using functional or histological end points were selected for analysis. Relationships between outcome, drug mechanism, scope of testing, and clinical trial status were assessed statistically. Results: There was no evidence that drugs used clinically (114 drugs) were more effective experimentally than those tested only in animal models (912 drugs), for example, improvement in focal models averaged 31.3 ± 16.7% versus 24.4 ± 32.9%, p > 0.05, respectively. Scope of testing using Stroke Therapy Academic Industry Roundtable (STAIR) criteria was highly variable, and no relationship was found between mechanism and efficacy. Interpretation: The results question whether the most efficacious drugs are being selected for stroke clinical trials. This may partially explain the slow progress in developing treatments. Greater rigor in the conduct, reporting, and analysis of animal data will improve the transition of scientific advances from bench to bedside. Ann Neurol 2006
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ischemic Cell Death in Brain Neurons
Lipton, P. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1431 · Cited by 3,043
Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug Development
(1999) · Stroke · doi:10.1161/01.str.30.12.2752 · Cited by 1,251
Pooling of Animal Experimental Data Reveals Influence of Study Design and Publication Bias
Macleod, M. R., O’Collins, T., Howells, D. W., & Donnan, G. A. (2004) · Stroke · doi:10.1161/01.str.0000125719.25853.20 · Cited by 730
Self-citationGladstone, D. J., Black, S. E., & Hakim, A. M. (2002) · Stroke · doi:10.1161/01.str.0000025518.34157.51 · Cited by 635
Where is the evidence that animal research benefits humans?
Pound, P., Ebrahim, S., Sandercock, P., Bracken, M. B., & Roberts, I. (2004) · BMJ · doi:10.1136/bmj.328.7438.514 · Cited by 505
Multiple Molecular Penumbras after Focal Cerebral Ischemia
Sharp, F. R., Lu, A., Tang, Y., & Millhorn, D. E. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200007000-00001 · Cited by 403
Neuroprotection for ischemic stroke: Two decades of success and failure
Cheng, Y. D., Al-Khoury, L., & Zivin, J. A. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.36 · Cited by 384
Systematic Review and Metaanalysis of the Efficacy of FK506 in Experimental Stroke
Macleod, M. R., O'Collins, T., Horky, L. L., Howells, D. W., & Donnan, G. A. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600064 · Cited by 176
Self-citationAnimal models of stroke: do they have value for discovering neuroprotective agents?
Richard Green, A., Odergren, T., & Ashwood, T. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00192-5 · Cited by 168
Hunter, A. J., Mackay, K. B., & Rogers, D. C. (1998) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01157-7 · Cited by 162
Buchan, A. M., Gertler, S. Z., Li, H., Xue, D., Huang, Z., Chaundy, K. E., Barnes, K., & Lesiuk, H. J. (1994) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1994.121 · Cited by 140
Systematic review and meta‐analysis of the efficacy of melatonin in experimental stroke
Macleod, M. R., O'Collins, T., Horky, L. L., Howells, D., & Donnan, G. A. (2005) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2004.00172.x · Cited by 137
Self-citationWhich Targets Are Relevant for Therapy of Acute Ischemic Stroke?
Heiss, W., Thiel, A., Grond, M., & Graf, R. (1999) · Stroke · doi:10.1161/01.str.30.7.1486 · Cited by 136
Numagami, Y., Sato, S., & OHNISHI, S. T. (1996) · Neurochemistry International · doi:10.1016/0197-0186(95)00117-4 · Cited by 134
Clinical trials for cytoprotection in stroke
Labiche, L. A., & Grotta, J. C. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.1.46 · Cited by 123
Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia
van der Worp, H. B., de Haan, P. S., Morrema, E., & Kalkman, C. J. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0802-3 · Cited by 120
Neuroprotection Is Unlikely to Be Effective in Humans Using Current Trial Designs
Grotta, J. C. (2002) · Stroke · doi:10.1161/str.33.1.306 · Cited by 117
Backhauβ, C., & Krieglstein, J. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90037-5 · Cited by 92
Why do all drugs work in animals but none in stroke patients ? 1 Drugs promoting cerebral blood flow
del Zoppo, G. J. (1995) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1995.tb01144.x · Cited by 75
Meng, W., Wang, X., Asahi, M., Kano, T., Asahi, K., Ackerman, R. H., & Lo, E. H. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199912000-00004 · Cited by 64
Neuroprotection for Ischaemic Stroke: An Unattainable Goal?
Liebeskind, D. S., & Kasner, S. E. (2001) · CNS Drugs · doi:10.2165/00023210-200115030-00001 · Cited by 55
Nagai, N., Vanlinthout, I., & Collen, D. (1999) · Circulation · doi:10.1161/01.cir.100.25.2541 · Cited by 39
Research works printed but not linked: 3
- Cochrane Central Register of Controlled Trials (CENTRAL).2005.The Cochrane Collaboration John Wiley & Sons Ltd.
- Sharma SS, 2003, Emerging neuroprotective approaches in stroke treatment, Current Research & Information on Pharmaceutical Sciences, 4, 8
- Huang R, 1999, [Effects of defibrinogenase on photochemically induced middle cerebral artery occlusion in stroke‐prone renovascular hypertensive rats], Zhonghua Yi Xue Za Zhi, 79, 711
Cited by
Jauch, E. C., Saver, J. L., Adams, H. P., Bruno, A., Connors, J. J. (., Demaerschalk, B. M., Khatri, P., McMullan, P. W., Qureshi, A. I., Rosenfield, K., et al. (2013) · Stroke · doi:10.1161/str.0b013e318284056a · Cited by 7,634
Campbell, B. C. V., De Silva, D. A., Macleod, M. R., Coutts, S. B., Schwamm, L. H., Davis, S. M., & Donnan, G. A. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0118-8 · Cited by 1,750
Self-citationCan Animal Models of Disease Reliably Inform Human Studies?
van der Worp, H. B., Howells, D. W., Sena, E. S., Porritt, M. J., Rewell, S., O'Collins, V., & Macleod, M. R. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000245 · Cited by 1,354
Self-citationThe Mystery and Magic of Glia: A Perspective on Their Roles in Health and Disease
Barres, B. A. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.013 · Cited by 1,352
Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations
Fisher, M., Feuerstein, G., Howells, D. W., Hurn, P. D., Kent, T. A., Savitz, S. I., & Lo, E. H. (2009) · Stroke · doi:10.1161/strokeaha.108.541128 · Cited by 1,352
Self-citation
Metadata
- Authors
- O'Collins, V. E., Macleod, M. R., Donnan, G. A., Horky, L. L., van der Worp, B. H., & Howells, D. W.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2006-02-17
- Volume
- 59
- Issue
- 3
- Pages
- 467-477
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2157368934
- Cited by
- 1,460
- References
- 22
- FWCI
- 36.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.